These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related]
6. IFN-β Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status. Severa M; Rizzo F; Giacomini E; Annibali V; Gafa V; Romano S; Buscarinu MC; Fornasiero A; Salvetti M; Coccia EM J Interferon Cytokine Res; 2015 Sep; 35(9):668-81. PubMed ID: 25923141 [TBL] [Abstract][Full Text] [Related]
7. Correlation between Type I Interferon Associated Factors and COVID-19 Severity. Bencze D; Fekete T; Pázmándi K Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142877 [TBL] [Abstract][Full Text] [Related]
8. Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-γ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome. Caldarale F; Giacomelli M; Garrafa E; Tamassia N; Morreale A; Poli P; Timpano S; Baresi G; Zunica F; Cattalini M; Moratto D; Chiarini M; Cannizzo ES; Marchetti G; Cassatella MA; Taddio A; Tommasini A; Badolato R Front Immunol; 2021; 12():654587. PubMed ID: 33841438 [TBL] [Abstract][Full Text] [Related]
9. Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2. Venet M; Ribeiro MS; Décembre E; Bellomo A; Joshi G; Nuovo C; Villard M; Cluet D; Perret M; Pescamona R; Paidassi H; Walzer T; Allatif O; Belot A; Trouillet-Assant S; Ricci EP; Dreux M Nat Commun; 2023 Feb; 14(1):694. PubMed ID: 36755036 [TBL] [Abstract][Full Text] [Related]
10. Efficient sensing of avian influenza viruses by porcine plasmacytoid dendritic cells. Bel M; Ocaña-Macchi M; Liniger M; McCullough KC; Matrosovich M; Summerfield A Viruses; 2011 Apr; 3(4):312-330. PubMed ID: 21994734 [TBL] [Abstract][Full Text] [Related]
11. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. Solimani F; Meier K; Ghoreschi K Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065 [TBL] [Abstract][Full Text] [Related]
12. Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings. Greene TT; Zuniga EI Viruses; 2021 Sep; 13(9):. PubMed ID: 34578420 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells. Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952 [TBL] [Abstract][Full Text] [Related]
14. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Galani IE; Rovina N; Lampropoulou V; Triantafyllia V; Manioudaki M; Pavlos E; Koukaki E; Fragkou PC; Panou V; Rapti V; Koltsida O; Mentis A; Koulouris N; Tsiodras S; Koutsoukou A; Andreakos E Nat Immunol; 2021 Jan; 22(1):32-40. PubMed ID: 33277638 [TBL] [Abstract][Full Text] [Related]
15. Human Nasal and Lung Tissues Infected Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170 [TBL] [Abstract][Full Text] [Related]
16. Human plasmacytoid dendritic cells at the crossroad of type I interferon-regulated B cell differentiation and antiviral response to tick-borne encephalitis virus. Etna MP; Signorazzi A; Ricci D; Severa M; Rizzo F; Giacomini E; Gaggioli A; Bekeredjian-Ding I; Huckriede A; Coccia EM PLoS Pathog; 2021 Apr; 17(4):e1009505. PubMed ID: 33857267 [TBL] [Abstract][Full Text] [Related]
17. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Gibson SJ; Lindh JM; Riter TR; Gleason RM; Rogers LM; Fuller AE; Oesterich JL; Gorden KB; Qiu X; McKane SW; Noelle RJ; Miller RL; Kedl RM; Fitzgerald-Bocarsly P; Tomai MA; Vasilakos JP Cell Immunol; 2002; 218(1-2):74-86. PubMed ID: 12470615 [TBL] [Abstract][Full Text] [Related]
18. Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19. Laurent P; Yang C; Rendeiro AF; Nilsson-Payant BE; Carrau L; Chandar V; Bram Y; tenOever BR; Elemento O; Ivashkiv LB; Schwartz RE; Barrat FJ Sci Immunol; 2022 Sep; 7(75):eadd4906. PubMed ID: 36083891 [TBL] [Abstract][Full Text] [Related]
19. Blocking TLR7- and TLR9-mediated IFN-α production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection. Kader M; Smith AP; Guiducci C; Wonderlich ER; Normolle D; Watkins SC; Barrat FJ; Barratt-Boyes SM PLoS Pathog; 2013; 9(7):e1003530. PubMed ID: 23935491 [TBL] [Abstract][Full Text] [Related]